文献速递胸部肿瘤

帕博利珠单抗联合CC-486对比帕博利珠单抗联合安慰剂治疗经治晚期非小细胞肺癌的随机2期研究

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2019-01-14

这项随机2期研究纳入100例既往接受过一线含铂治疗的晚期非小细胞肺癌患者,按1:1随机分配至帕博利珠单抗联合CC-486(口服阿扎胞苷)组或帕博利珠单抗联合安慰剂组。结果显示两组无进展生存期无显著差异,联合CC-486组治疗暴露时间更短,治疗期间不良事件更多,以胃肠道不良事件为主。

要点

  • 帕博利珠单抗联合CC-486组与联合安慰剂组的中位无进展生存期分别为2.9个月和4.0个月,无显著差异(HR 1.374,90%CI 0.926-2.038,P=0.1789)。
  • 联合CC-486组中位总生存期为11.9个月,联合安慰剂组未达可估计值(HR 1.375,90%CI 0.830-2.276,P=0.2968);客观缓解率分别为20%和14%。
  • 联合CC-486组治疗期间不良事件更常见,以胃肠道不良事件为主,可能影响治疗可行性。

核心结论

  • 帕博利珠单抗联合CC-486较帕博利珠单抗联合安慰剂未观察到无进展生存期改善。
  • 因不良事件导致的治疗暴露减少可能影响了帕博利珠单抗联合CC-486的疗效。

研究设计与样本

  • 随机2期试验,纳入既往接受过一线含铂治疗的晚期非小细胞肺癌患者。
  • 按1:1随机分配至CC-486组或安慰剂组,CC-486或安慰剂于第1-14天给药,帕博利珠单抗于21天周期第1天给药。
  • 共随机100例患者,帕博利珠单抗联合CC-486组51例,帕博利珠单抗联合安慰剂组49例。
  • 主要终点为无进展生存期,关键次要终点包括总生存期、客观缓解率和安全性。

主要发现

  • 帕博利珠单抗联合CC-486组与帕博利珠单抗联合安慰剂组中位无进展生存期分别为2.9个月和4.0个月(HR 1.374,90%CI 0.926-2.038,P=0.1789),无显著差异。
  • 帕博利珠单抗联合CC-486组中位总生存期为11.9个月,帕博利珠单抗联合安慰剂组未达可估计值(HR 1.375,90%CI 0.830-2.276,P=0.2968)。
  • 帕博利珠单抗联合CC-486组与帕博利珠单抗联合安慰剂组客观缓解率分别为20%和14%。
  • 帕博利珠单抗联合CC-486组较帕博利珠单抗联合安慰剂组中位治疗持续时间更短(15.0周 vs 24.1周),周期数更少(5.0 vs 7.0)。
  • 未检测到CC-486或帕博利珠单抗新的安全性信号;帕博利珠单抗联合CC-486组治疗期间不良事件更常见,以胃肠道不良事件为主,可能影响治疗可行性。

关键数值与推荐

  • 入组患者为既往接受过一线含铂治疗的晚期非小细胞肺癌患者。
  • 100例患者中男性占57.0%,白人占87.0%,东部肿瘤协作组体能状态评分为1者占68.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Preclinical and early clinical studies suggest that combining epigenetic agents with checkpoint inhibitors can potentially improve outcomes in patients with previously treated advanced non-small cell lung cancer (NSCLC). This phase 2 trial examined second-line pembrolizumab + CC-486 (oral azacitidine) in patients with advanced NSCLC. METHODS: Patients with one prior line of platinum-containing therapy were randomised in a ratio of 1:1 to CC-486 or placebo, on days 1-14, in combination with pembrolizumab on day 1 of a 21-day cycle. The primary end-point was progression-free survival (PFS). Key secondary end-points included overall survival (OS), overall response rate (ORR) and safety. RESULTS: Among 100 patients randomised (pembrolizumab + CC-486: 51; pembrolizumab + placebo: 49), most were male (57.0%), were white (87.0%) and had Eastern Cooperative Oncology Group performance status 1 (68.0%). No significant difference in PFS was observed between the pembrolizumab + CC-486 and pembrolizumab + placebo arms (median, 2.9 and 4.0 months, respectively; hazard ratio [HR], 1.374; 90% confidence interval [CI], 0.926-2.038; P = 0.1789). Median OS was 11.9 months versus not estimable (HR, 1.375; 90% CI, 0.830-2.276; P = 0.2968); ORR was 20% versus 14%. Median treatment duration was shorter (15.0 versus 24.1 weeks), and the number of cycles was lower (5.0 versus 7.0) with pembrolizumab + CC-486 versus pembrolizumab + placebo. No new safety signals for CC-486 or pembrolizumab were detected. Treatment-emergent adverse events were more common in the pembrolizumab + CC-486 arm, particularly gastrointestinal, potentially impacting treatment feasibility. CONCLUSIONS: No improvement in PFS was observed with pembrolizumab + CC-486 versus pembrolizumab + placebo. Decreased treatment exposure due to adverse events may have impacted efficacy with pembrolizumab + CC-486.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Levy BP, Giaccone G, Besse B, et al. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer. 2019. PMID: 30654297. doi:10.1016/j.ejca.2018.11.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。